Xeomin- Frequently Asked Questions

Q: How Do I know if Xeomin is right for me?
Q: What should I expect during treatment
Q: When should I expect to see results
Q: Is Xeomin proven or approved?

Q: How Do I know if Xeomin is right for me?

If you are an adult with moderate to severe glabellar lines (frown lines between the eyes), XEOMIN® may be right for you. Talk to your doctor to discuss the benefits and risks of treatment.
Do not take XEOMIN® if you are allergic to botulinum toxin or any of the other ingredients in XEOMIN®. You should also not take XEOMIN® if you have had an allergic reaction to any other botulinum toxin product or have a skin infection at the planned injection site.

Q: What should I expect during treatment

During treatment, which usually takes about 10-20 minutes, your doctor will inject XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use, into the muscles in your forehead that cause frown lines between your brows. No anesthesia is required; however, your physician may use a topical anesthetic or cold pack to reduce any discomfort.

Q: When should I expect to see results

In clinical trials, some patients observed visible smoothing as early as 3-4 days after injection. The median first onset of effect was less than a week. The maximum effect occurred at 30 days. The typical duration of effect was up to 3 months in clinical trials but may last significantly longer or shorter in individual patients.

Q: Is Xeomin proven or approved?

XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use, was proven effective in two randomized, double-blind, multi-center, placebo-controlled clinical trials of more than 540 adult patients in the treatment of glabellar frown lines. The average age of patients in the study was 46 years. Patients received 20 Units of XEOMIN® and were classified as responders if they had a 2-grade improvement on a 4-point scale as assessed by the physician and patient. Using these criteria, treatment success was higher with XEOMIN® than placebo on day 30 in both studies (60% and 48% vs. 0% for placebo in both studies). Based on these trials, XEOMIN® received FDA approval for aesthetic use in 2011.